HomepageEVGN • NASDAQ
add
Evogene Ltd
Vorige slotkoers
$Â 1,38
Dag-range
$Â 1,36 - $Â 1,43
Jaar-range
$Â 1,20 - $Â 8,90
Beurswaarde
7,44Â mln. USD
Gem. volume
20,30K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,61Â mln. | 178,72% |
Bedrijfskosten | 5,42Â mln. | -30,55% |
Netto inkomsten | 427,00K | 106,47% |
Netto winstmarge | 26,51 | 102,32% |
Winst per aandeel | 0,06 | 104,62% |
EBITDA | -3,97Â mln. | 42,94% |
Effectief belastingtarief | 350,00% | — |
Balans
Totale activa
Totale passiva
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 15,31Â mln. | -50,71% |
Totale activa | 39,86Â mln. | -21,99% |
Totale passiva | 25,03Â mln. | 11,64% |
Totaal aandelenvermogen | 14,84 mln. | — |
Uitstaande aandelen | 6,80 mln. | — |
Koers-boekwaardeverhouding | -6,57 | — |
Rendement op activa | -28,55% | — |
Rendement op kapitaal | -75,45% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 427,00K | 106,47% |
Operationele kasstroom | -4,56Â mln. | 23,02% |
Kasstroom uit beleggingen | 8,76Â mln. | 1.594,54% |
Kasstroom uit financiering | -206,00K | -40,14% |
Nettomutatie in liquide middelen | 3,98Â mln. | 160,74% |
Vrije kasstroom | -9,39Â mln. | -154,28% |
Over
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
CEO
Opgericht
2002
Website
Werknemers
142